JPRN-jRCTs052200114进行中（未招募）4 期
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-3 study - STOPDAPT-3
Ono Koh0 个研究点目标入组 6,000 人开始时间: 2021年1月19日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •# Patients who are planned to have PCI with exclusive use of EES (XienceTM series).
- •# Patients with ARC-HBR or ACS
- •# Patients who could take DAPT with aspirin and P2Y12 inhibitors for 1-month
排除标准
- •# Patients who withdraw consent (Included in the safety analysis set)
研究者
相似试验
已完成
不适用
ShorT and OPtimal duration of Dual AntiPlatelet Therapy studycoronary artery diseaseJPRN-UMIN000008878Kyoto University Hospital1,500
进行中（未招募）
4 期
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-2 study for patients with ACSJPRN-jRCTs052180193Ono Koh3,000
进行中（未招募）
1 期
Optimal duration of dual anti-platelet therapy in patients undergoing endovascular revascularization of the superficial femoral artery.Patients with diagnosis of lower limbs PAOD, ranging from stage 2 to 5 according to Rutherford classification and lesions of the SFA treated by endovascular revascularizationMedDRA version: 20.0Level: LLTClassification code 10016430Term: Femoral artery stenosisSystem Organ Class: 100000004866EUCTR2018-000532-94-ITFONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO78
进行中（未招募）
不适用
Optimal duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms: A prospective randomized multicenter trialDiseases of the circulatory systemKCT0006651Seoul National University Bundang Hospital528
招募中
不适用
DURATIODiseases of the circulatory systemKCT0004407Seoul National University Bundang Hospital4,748